EN DE
Watch Bicara Therapeutics Inc. Common Stock for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Bicara Therapeutics Inc. (BCAX) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Bicara Therapeutics Inc. stock $5.04, price $8.65, that is 41.7% below the price, quality 26 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

BT Bicara Therapeutics Inc. logo Thin data Nov 6, 2026

Bicara Therapeutics Inc.

BCAX · US
Very expensive, weak quality

Our calculation puts a fair price 42% below what the stock costs today.

Mixed vs. peers (4/7)
Insiders sold $4.2M (6M)
Fair value $5.04 · Strongly overvalued
Quality 26/100
Negative free cash flow
Narrow moat 12/100
Negative coverage
Thin data
⚠ Dilution
Watch Bicara Therapeutics Inc. Common Stock for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$30.40 $7.93 Fair Value $5.04 Sep 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

26‑month range $7.93 – $30.40 · fair‑value band $3.32 – $6.30 · the $8.65 price screens above the $5.04 fair value. As of Nov 6, 2026.

Follow Bicara Therapeutics Inc. Common Stock in your weekly email

Every Wednesday you see whether Bicara Therapeutics Inc. Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors.

Show moreShow less

Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.

The company was incorporated in 2018 and is based in Boston, Massachusetts.

Stock analysis

Bicara Therapeutics Inc. (BCAX) currently trades at $8.65, while our model-based Fair Value estimate is $5.04, 42% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 92/100, which puts the data coverage at low.

Scenario range: $3.32 (bear) to $6.30 (bull), the price of $8.65 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.

Bicara Therapeutics Inc. Common Stock reported revenue of $0 in FY2025 versus $0 in FY2022. Reported net income was −$138M in FY2025.

Key figures

Market cap $588M Small · EPS (TTM) $−3.06 · Return on equity −41.0% · Return on assets (EBIT) −157% (4-year average) · Free cash flow −$107M · Net cash $95.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 72% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −42%, BCAX screens richer than that median.

Fair Value models

Bear $3.32 Fair Value $5.04 Bull $6.30
Price $8.65 · Downside -41.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $3.91 $5.93 $7.41 52
All 1 models by family
Asset-Based
NCAV (Graham) $3.91 $5.93 $7.41 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 26/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 18
Do the profits arrive as real cash?
Financial strength 94
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 15
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 3 officers or directors sold shares worth $4.2M and none bought.

  • SaleRyan CohlheppPresident, COO & Interim CEO, Director12× since Nov 21, 2025: 152,500 shares, avg. $22.68$3.5MSep 8, 202610b5-1 plan
  • SaleClaire MazumdarChief Executive Officer, Director8× since Nov 24, 2025: 151,163 shares, avg. $20.75$3.1MAug 10, 202610b5-1 plan
  • SaleIvan HyepChief Financial Officer9× since Nov 21, 2025: 114,100 shares, avg. $22.54$2.6MAug 10, 202610b5-1 plan
  • SaleDavid RabenChief Medical Officer4× since Nov 24, 2025: 38,500 shares, avg. $19.24$740,726Apr 27, 202610b5-1 plan
  • BuyRA CAPITAL MANAGEMENT, L.P.Director, 10% owner300,000 shares at $16.00$4.8MFeb 26, 2026

Plus 10 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

BCAX screens overvalued: fair value 42% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (49 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Negative
Recent news coverage is more negative than average.

Compare Bicara Therapeutics Inc. Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 557 stocks

Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside −41.7% · Above median
Profitability
Return on assets −32.0% · Below median
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.46× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs BCAX
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs BCAX
Genmab A/S GMAB kr 3,527 kr 3,999 +13% vs BCAX
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs BCAX
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs BCAX
Vertex Pharmaceuticals Incorporated VRTX $547.09 $596.75 +9% vs BCAX
argenx SE ARGX $927.21 $908.40 −2% vs BCAX
CSL Limited CSL A$202.04 A$183.04 −9% vs BCAX
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs BCAX
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs BCAX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Bicara Therapeutics Inc. Common Stock: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Bicara Therapeutics Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/BCAX

Frequently asked questions

Is Bicara Therapeutics Inc. (BCAX) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $5.04 versus a price of $8.65, about 42% lower (overvalued).
What is the fair value of BCAX?
Our model-based fair value for Bicara Therapeutics Inc. is $5.04 (as of Nov 6, 2026), built from audited fundamentals. The current price: $8.65.
What is the quality score of BCAX?
Bicara Therapeutics Inc. has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bicara Therapeutics Inc. (BCAX)?
Our model-based price target is the fair value of $5.04 (as of Nov 6, 2026) from 1 valuation models. Cautious scenario $3.32, optimistic scenario $6.30. It is a calculation from audited fundamentals, not an analyst target.
What is the Bicara Therapeutics Inc. Common Stock stock forecast for 2026?
Our models put fair value at $5.04, about 42% lower versus a price of $8.65 (overvalued). Cautious scenario $3.32, optimistic scenario $6.30. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Bicara Therapeutics Inc. (BCAX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bicara Therapeutics Inc. it is $5.04 per share (as of Nov 6, 2026), against a price of $8.65. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Bicara Therapeutics Inc. Common Stock stock overvalued or undervalued in 2026?
As of Nov 6, 2026, BCAX trades above its calculated fair value: price $8.65, fair value $5.04, a gap of about −42% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BCAX?
No. The price is what the market pays today ($8.65); the fair value is what the company's own numbers justify ($5.04). For Bicara Therapeutics Inc. the two are $3.61 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bicara Therapeutics Inc. Common Stock worth?
The market values Bicara Therapeutics Inc. at about $588M (market capitalisation, as of Nov 6, 2026). Per share that is $8.65; our models calculate a fair value of $5.04 per share.
What do the bullish and bearish scenarios say about BCAX?
Our models span a range for Bicara Therapeutics Inc.: cautious scenario $3.32, base $5.04, optimistic $6.30 per share (as of Nov 6, 2026, price $8.65). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Bicara Therapeutics Inc. (BCAX)?
Balance-sheet figures for Bicara Therapeutics Inc. (as of Nov 6, 2026): return on equity −41.0%. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is BCAX from its 52-week high?
Bicara Therapeutics Inc. trades at $8.65, about 72% below its 52-week high of $30.40 and 9% above the low of $7.93 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $5.04 is for.
Which stocks are comparable to Bicara Therapeutics Inc. Common Stock?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bicara Therapeutics Inc. Common Stock stock attractive at the current price?
The data as of Nov 6, 2026: price $8.65, calculated fair value $5.04 (−42%), Quality Score 26/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BCAX calculated?
We run Bicara Therapeutics Inc. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $5.04 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Bicara Therapeutics Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bicara Therapeutics Inc. (BCAX)?
The closing price on Nov 6, 2026 was $8.65. Our model-based fair value is $5.04, about 42% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bicara Therapeutics Inc. Common Stock right now?
The price sits above even our optimistic bull case ($6.30). The favourable scenario is already priced in. Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($3.32 to $6.30) leaves room in how you read the outcome.

Key figures of Bicara Therapeutics Inc.

How large is the market capitalisation of Bicara Therapeutics Inc. (BCAX)?
The market capitalisation of Bicara Therapeutics Inc. is $588M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Bicara Therapeutics Inc. (BCAX)?
Earnings per share at Bicara Therapeutics Inc. are $−3.06. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Bicara Therapeutics Inc. (BCAX)?
The return on equity (ROE) of Bicara Therapeutics Inc. is −41.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bicara Therapeutics Inc. (BCAX)?
On an EBIT basis the return on assets of Bicara Therapeutics Inc. is −157% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Bicara Therapeutics Inc. (BCAX) generate?
The free cash flow of Bicara Therapeutics Inc. is −$107M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Bicara Therapeutics Inc. (BCAX) hold?
Bicara Therapeutics Inc. holds more cash than debt, $95.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Bicara Therapeutics Inc. Common Stock in the live analysis

One click puts Bicara Therapeutics Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.